We are seeking a hands-on, highly motivated, talented Research Scientist to join our High-Throughput Screening group. This individual will focus on ex-vivo or in-vitro cell based assay development and optimization for drug candidate profiling and screening in support of Notable’s multiple projects. The candidate will serve as a team lead and provide expertise in identifying and implementing biological assays using our state of the art technology. He/she will be responsible for assisting in the design, development and optimization of our many external projects, including both our biotech and clinical partnerships, and development of continuous platform improvements. Emphasis will be on helping to design and implement complex assays not currently run through our unique platform. The candidate should have a proven record of applying sound scientific judgement to answer critical questions, as well as a proven ability to design and implement appropriate experiments. Strong organizational skills and multi-tasking ability are required. The right candidate should also be very comfortable with working different types of automated high throughput equipment. Ability to work independently in a high pace, multi-disciplinary environment is essential. Direct experience in hematology-oncology, drug discovery research and/or high-throughput screening strongly preferred.
Notable Labs is a precision medicine company that has a translational drug discovery platform focused on identifying novel therapeutic options for cancer patients.
Our clinical research lab helps oncologists identify personalized and rational combinations of treatments for patients. We’ve developed a high throughput robotic flow cytometry lab platform that screens thousands of FDA-approved and investigational drug combinations against the patient’s own cancer cells to help predict safer and more effective cancer treatments. Our lab has completed initial feasibility studies with clinicians in relapsed Acute Myeloid Leukemia & Myelodysplastic Syndrome, with an 84% predictive rate. Focusing on individual patients and existing treatments, we’re working to discover novel uses of drugs and defining mechanisms underlying cancer progression and drug resistance.
Our research and development platform extends our clinical research to drug discovery, testing novel compounds with primary patient samples for pharmaceutical and biotechnology companies. Using our automated, high-throughput, multi-parametric drug screening research platform, industry partners can assay the biological impact of novel compounds on primary cells in a physiologically relevant environment. This helps our partners stratify patients by their predicted responsiveness, increasing the probability of successful clinical development. We are actively partnering with pharmaceutical companies that have preclinical and clinical stage drug pipelines in Acute Myeloid Leukemia, Myelodysplastic Syndrome, or related hematological malignancies to profile experimental drug activity in patient samples.
Our investors include Builders Venture Capital, Founders Fund, First Round Capital, Y Combinator, several prominent angels and seed-stage funds, and Accelerate Brain Cancer Cure, a venture philanthropy firm founded by Steve Case.
At Notable Labs we value diversity and are an equal opportunity employer. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.ᐧ